We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
MAYZENT (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
MAYZENT
Date registered
Evaluation commenced
Decision date
Approval time
209 working days (255)
Active ingredients
siponimod
Registration type
NCE/NBE
Indication
MAYZENT (film-coated tablet) is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS).